Technologies

Clinically relevant breast cancer cell line that can be used to test and validate novel therapeutics for tamoxifen resistant breast cancer.

• UIC researchers have developed several clinically relevant breast cancer cell lines in order to investigate the antitumor effects of novel benzothiophene selective estrogen mimics (SEM).
• Among these, the T47D:A18-TAM1 cell line shows an endogenous resistance to tamoxifen. The cells also exhibit an increased expression of Protein Kinase C alpha (PKCα) which is an important player in tamoxifen resistant breast cancer.
• The cell line has been used in in-vitro studies as well as to generate in-vivo mouse xenograft tumor models.
• The culture conditions, morphology and growth behavior of the cell line is well characterized and they have been authenticated using short tandem repeat (STR) and ATCC analysis.
• These cells have been designed to test and validate novel therapeutics for tamoxifen resistant breast cancer.